Orion Oyj (ORINF) Stock Price & Analysis
Orion Oyj (ORINF) closed at USD 92.05 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 92.05; the Oct 22, 2026 session ranged USD 96.86–96.86 on volume of 14 shares. Market capitalization is $12.92B, with a 52-week range of USD 78.95–96.86 (PNK). Source: Nexqual, retrieved October 23, 2026 at 16:39 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ORINF.md
Key facts (ORINF)
- Analysts: None.
- Total return with dividends: 1Y +15.7% vs S&P 500 +14.6%; 5Y +148.8% vs S&P 500 +77.3%.
- Next earnings: 2026-10-28, EPS estimate USD —, revenue estimate $538M.
Analysts (ORINF)
Consensus None.
Total return (dividends reinvested) (ORINF)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +15.7% | +148.8% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | +15.7% | +20.0% |
| Volatility (annualized) | 12.1% | 28.7% |
| Max drawdown | -2.9% (Oct 2025→Feb 2026) | -20.7% (Apr 2023→Aug 2023) |
ORINF analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $538.0M | — |
| Next quarter (ends Dec 2026) | — | — | — | $632.1M | — |
| Current fiscal year (ends Dec 2026) | — | — | — | $2.10B | — |
| Next fiscal year (ends Dec 2027) | — | — | — | $2.38B | — |
Key Statistics (as of October 23, 2026 at 16:39 UTC)
| Price | USD 92.05 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 92.05 |
| Open | USD 96.86 |
| Day Range | USD 96.86 – 96.86 |
| 52-Week Range | USD 78.95 – 96.86 |
| Volume | 14 shares |
| Market Cap | $12.92B |
| Exchange | PNK |
Technical Analysis (ORINF)
Nexqual's technical model rates ORINF "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 16:39 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Above (USD 88.52) |
| MACD | 0.8 (positive) |
Analyst Ratings (ORINF)
Wall Street analysts rate ORINF "None", per Nexqual as of October 23, 2026 at 16:39 UTC.
| Consensus Rating | None |
|---|
Earnings (ORINF)
| Next Earnings Date | 2026-10-28 |
|---|---|
| Revenue Estimate | $538.04M |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Financials & Fundamentals (ORINF)
| Total Revenue | $2.06B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +25.20% |
| Gross Margin | +65.93% |
| Operating Margin | +33.84% |
| Profit Margin | +28.53% |
| ROE | +53.65% |
| Debt / Equity | 0.1 |
| Current Ratio | 2.64 |
| Total Cash | $130.20M |
| Total Debt | $132.70M |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Financial Health Score (ORINF)
Nexqual rates Orion Oyj's overall financial health "Strong" across five dimensions, as of October 23, 2026 at 16:39 UTC.
| Growth | Strong — Revenue +23% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 66%, operating 34% (last 12 months) |
| Balance Sheet | Strong — EUR 130M cash vs EUR 133M debt |
| Cash Flow | Solid — Operating cash flow EUR 472M (TTM) |
| Efficiency | Strong — ROE 54%, ROA 26.3% |
Ownership (ORINF)
| Insider Ownership | +2.63% |
|---|---|
| Institutional Ownership | +45.72% |
| Shares Outstanding | 108.99M |
| Float | 123.43M |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Leadership (ORINF)
Orion Oyj is led by Liisa Hurme, President, CEO & Chairman of Executive Management Board, per Nexqual as of October 23, 2026 at 16:39 UTC.
| President, CEO & Chairman of Executive Management Board | Liisa Hurme |
|---|---|
| CFO & Member of Group Executive Management Board | Rene Lindell M.Sc. |
| Executive Vice President of Innovative Medicines & Member of Management Board | Berkeley Vincent |
Major Backers & Investors (ORINF)
Notable institutional backers of Orion Oyj include DFA INVESTMENT TRUST CO-The Continental Small Company Series, Fidelity, according to Nexqual as of October 23, 2026 at 16:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DFA INVESTMENT TRUST CO-The Continental Small Company Series | 1% |
| Fidelity | 0.39% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.82% |
| BlackRock | 1.1% |
| State Street | 0.35% |
Source: Nexqual, October 23, 2026 at 16:39 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GRFS | Grifols, S.A. | USD 7.55 | ▲ 1.28% |
| BIIB | Biogen Inc. | USD 250.61 | ▼ 1.27% |
| OGN | Organon & Co. | USD 13.76 | ▲ 0.07% |
| SNY | Sanofi | USD 41.48 | ▼ 1.14% |
| GSK | GSK plc | USD 50.6 | ▼ 1.19% |
| BMY | Bristol-Myers Squibb Company | USD 61.76 | ▼ 1.97% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:39 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt